+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

‘Global Plasma Fractionation Market Set To Grow To $40bn By 2023’ says newly published Visiongain research

30 July 2018
Pharma

Visiongain’ has launched a new pharma report Global Plasma Fractionation 2018-2028: Immunoglobulins, Albumins, Clotting Factors, Hyperimmune Globulins, Alpha 1 Antitrypsin Inhibitors (A1PI), C1 Esterase Inhibitors, Primary Immune Deficiency (PID), Secondary Immune Deficiency (SID), Idiopathic Thrombocytopenic Purpura (ITP), Cardiac & Surgery, Emergency Medicine, Haemophilia

In this report, we examined the global plasma fractionation market including the major submarkets by product, application, region and national market. The industry consists of a small number of high-capacity commercial fractionators with extensive multinational operations, and a large number of medium to small fractionators, which have lower outputs and exist primarily to serve national markets.

The lead analyst of the report commented “Aside from the growth in the scale of the industry, there has been an increasing sophistication in the processes that ensure the safety and quality of products; a greater use of chromatography in fractionation technologies; a concentration of the industry into fewer hands; and shifts in the patterns of clinical usage for the various plasma-fractionated products. The key drivers of demand for fractionation services have also changed over time as new plasma products have become commercially available and new indications for the use of plasma products have been identified and adopted.”

Leading companies featured in the report include

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 208 781 6953

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read